Drug intelligence / Profile preview

abatacept + Humulin R

Development stage: Unknown
Lead developer: Bristol Myers Squibb
Modality: Recombinant Proteins and Enzymes, Small Molecules
Administration: Intravenous, Subcutaneous

Overview

This is a combination of two distinct medications. **Abatacept** is a selective costimulation modulator (immunomodulator) that works by blocking the activity of T-cells, reducing inflammation and joint damage in autoimmune conditions. It's primarily used to treat rheumatoid arthritis, psoriatic arthritis, and juvenile idiopathic arthritis. **Humulin R** is a short-acting regular insulin that helps control blood glucose levels in patients with diabetes by enabling carbohydrate metabolism and preventing ketone body production by the liver.

Targets

CD80 (T-lymphocyte activation antigen CD80)INSR (Insulin receptor)CD86 (T-lymphocyte activation antigen CD86)

Beyond the preview

Go deeper on abatacept + Humulin R.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on abatacept + Humulin R.

Explore the full profile